Electrospun aligned tacrolimus-loaded polycaprolactone biomaterials for peripheral nerve repair.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING

Regenerative medicine Pub Date : 2024-04-01 Epub Date: 2023-10-11 DOI:10.2217/rme-2023-0151

Holly N Gregory, Owein Guillemot-Legris, Daisy Crouch, Gareth Williams, James B Phillips

引用次数: 0

Abstract

Background: Efficacious repair of peripheral nerve injury is an unmet clinical need. The implantation of biomaterials containing neurotrophic drugs at the injury site could promote nerve regeneration and improve outcomes for patients. Materials & methods: Random and aligned electrospun poly-ε-caprolactone scaffolds containing encapsulated tacrolimus were fabricated, and the gene expression profile of Schwann cells (SCs) cultured on the surface was elucidated. On aligned fibers, the morphology of SCs and primary rat neurons was investigated. Results: Both scaffold types exhibited sustained release of drug, and the gene expression of SCs was modulated by both nanofibrous topography and the presence of tacrolimus. Aligned fibers promoted the alignment of SCs and orientated outgrowth from neurons. Conclusion: Electrospun PCL scaffolds with tacrolimus hold promise for the repair of peripheral nerve injury.

查看原文本刊更多论文

电纺定向他克莫司负载聚己内酯生物材料用于外周神经修复。

背景：外周神经损伤的有效修复是一个尚未满足的临床需求。在损伤部位植入含有神经营养药物的生物材料可以促进神经再生，改善患者的预后。材料与方法：制备了含有他克莫司胶囊的随机排列的电纺聚ε-己内酯支架，并阐明了表面培养的施旺细胞的基因表达谱。在排列的纤维上，研究了SC和原代大鼠神经元的形态。结果：两种支架类型都表现出药物的持续释放，并且SCs的基因表达受到纳米纤维形貌和他克莫司的存在的调节。排列的纤维促进了SC的排列，并定向了神经元的生长。结论：他克莫司电纺PCL支架有望修复周围神经损伤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.